EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device

Benzinga_recent_news04-09 19:33

Nexalin Technology, Inc. (NASDAQ:NXL) on Thursday announced another publication of a peer-reviewed study in BMC Psychiatry related to the company's Deep Intracranial Frequency Stimulation (DIFS) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626818171?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/09/Agitated-Depression-Mentioned.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-09 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626818171","market":"sh","top_or_hot":-1,"title":"EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device","media":"Benzinga_recent_news","content":"<div>\n<p>Nexalin Technology, Inc. (NASDAQ:NXL) on Thursday announced another publication of a peer-reviewed study in BMC Psychiatry related to the company's Deep Intracranial Frequency Stimulation (DIFS) ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/04/51726153/exclusive-nexalin-study-flags-reduced-self-injury-in-adolescents-using-brain-stimulation-device\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-09 19:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/04/51726153/exclusive-nexalin-study-flags-reduced-self-injury-in-adolescents-using-brain-stimulation-device><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nexalin Technology, Inc. (NASDAQ:NXL) on Thursday announced another publication of a peer-reviewed study in BMC Psychiatry related to the company's Deep Intracranial Frequency Stimulation (DIFS) ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/04/51726153/exclusive-nexalin-study-flags-reduced-self-injury-in-adolescents-using-brain-stimulation-device\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NXL","symbol_name":"Nexalin Technology, Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/04/51726153/exclusive-nexalin-study-flags-reduced-self-injury-in-adolescents-using-brain-stimulation-device","article_id":"2626818171","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/09/Agitated-Depression-Mentioned.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/04/51726153/exclusive-nexalin-study-flags-reduced-self-injury-in-adolescents-using-brain-stimulation-device","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626818171","pubTimestamp":1775734380,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Nexalin study shows reduced self-injury and depression in adolescents using DIFS, with brain connectivity changes and early safety data.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NXL":"Nexalin Technology, Inc.","BK4082":"医疗保健设备"},"translate_title":"独家：Nexalin研究表明使用脑刺激设备减少了青少年的自残","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXL":1},"content_text":"Nexalin Technology, Inc. (NASDAQ:NXL) on Thursday announced another publication of a peer-reviewed study in BMC Psychiatry related to the company's Deep Intracranial Frequency Stimulation (DIFS) technology.\nThe data reported that Nexalin's DIFS 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with non-suicidal self-injury (NSSI).\nThe study also reported measurable changes in brain-network activity and connectivity, providing additional neurophysiological evidence supporting Nexalin's non-invasive, high-power DIFS technology.\nThe analysis evaluated six female adolescent patients who received 21 days of 77.5 Hz, 15 mA stimulation using Nexalin's device.\nThe paper found changes in functional connectivity across emotional-control networks, including Default, Limbic, Salience/Ventral Attention, and Control networks.\nThe findings also showed improvement in anxiety and sleep quality measures.\nNo significant adverse effects were observed, with only one mild headache reported that resolved quickly.\nThe authors described the findings as preliminary evidence supporting further investigation in larger randomized controlled trials.\nMark White, CEO of Nexalin, added, \"The Nexalin 15 mAmp DIFS technology allows for deeper penetration, which supports higher efficacy and enhanced treatment outcomes in a treatment-resistant population. In a market seeking safer, drug-free alternatives in mental health, each additional peer-reviewed publication helps further validate our technology and broaden its relevance across multiple indications.\"\nIn February, Nexalin launched its new AI-designed virtual clinic platform, NeuroCare, in collaboration with the University of California, San Diego.\nThe launch marked the first step in deploying Nexalin's digital health ecosystem, designed to increase patient access, reduce costs, and provide long-term physician-patient care and monitoring across critical brain-health indications.\nNXL Stock Price Activity: Nexalin shares closed at $0.35 on Wednesday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626818171","isCrawlerRequest":true}